Study on FG-3246 for Treating Advanced Prostate Cancer Resistant to Hormone Therapy

Inclusion Criteria

• Must have a confirmed diagnosis of prostate cancer.
• Must agree to a biopsy of a tumor if it can be safely accessed, or provide a recent biopsy sample.
• Must have low testosterone levels, or be on medication to keep testosterone low if they haven't had surgery to remove the testicles.
• Must have previously tried one hormone therapy drug like abiraterone or enzalutamide, and the cancer must have continued to grow after this treatment.
• Must have at least one tumor that can be seen on a scan taken within 28 days before starting the study.
• Must have good organ function as shown by medical tests before starting the study.

Exclusion Criteria

• Cannot have been treated with a drug that targets the CD46 protein before.
• Cannot have a type of prostate cancer called small cell neuroendocrine carcinoma.
• Cannot have tried more than one hormone therapy drug in the past.
• Cannot have had any cancer treatments like immunotherapy or radiation within 28 days before starting the study.
• Cannot have certain genetic mutations unless they have already tried and not responded to the specific treatments for those mutations.
• Cannot have had chemotherapy before, except for one specific type if it was completed over a year ago.
• Cannot be allergic to FG-3246 or similar drugs.
• Cannot have had another type of cancer in the last 5 years, except for certain skin cancers.
• Cannot be taking certain medications that affect how the body processes drugs.